Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?
Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?
What is covered in this report?
- Overview of China’s red biotechnology
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations
What benefits will you get?
- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology
- Keep informed of the precise development situation of key RB products with basic data and latest info
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields
- Figure out, current trend and future growth prospect of red biotechnology in China
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China SHOW LESS READ MORE >
Methodology & sources
I Overview of red biotechnology in China
Introduction to red biotechnology
Role of red biotechnology in medicine industry
Overview of red biotechnology development
II Development environment of red biotechnology in China
II-1 Macro economic environment
II-2 Policy environment
II-3 Medicine industry development
II-4 Venture capital
III Market segments of red biotechnology industry in China
III-1 Gene recombinant drugs
III-1.6 Anti-tumor monoclonal antibody
III-2 Blood products
III-3 Human vaccines
III-4 Diagnostic reagent
III-4.1 Diagnostic reagent history in China
III-4.2 Current production situation in China
III-4.3 Producers information of Chinese diagnostic reagent
III-4.3.1 Biochemical diagnostic reagent
III-4.3.2 Immunodiagnostic reagent
III-4.3.3 Molecular diagnostic reagent
III-18.104.22.168 PCR reagent
III-5 Other red biotechnology based drugs
III-5.1.1 Current antibiotic production in China
III-5.1.2 Penicillin production technology
III-5.1.3 Waste treatment technology
III-6 Forecast on supply & demand to the next 5~10 years
III-6.1 Forecast on gene recombinant market during 2010~2020
III-6.1.1 Supply of gene recombinant drugs during 2000~2020
III-6.1.2 Demand for gene recombinant drugs during 2009~2020
III-6.1.3 Difference between demand and supply during 2009~2020
III-6.2 Forecast on blood product market during 2010~2020
III-6.2.1 Supply of blood products during 2005~2020
III-6.2.2 Demand for blood products during 2009~2020
III-6.2.3 Difference between demand and supply during 2009~2020
III-6.3 Forecast on human vaccine market during 2010~2020
III-6.3.1 Supply of human vaccines during 2005~2020
III-6.3.2 Demand for human vaccines during 2009~2020
III-6.3.3 Difference between demand and supply during 2009~2020
III-6.4 Forecast on diagnostic reagent market during 2010~2020
III-6.4.1 Supply of diagnostic reagents during 2005~2020
III-6.4.2 Demand for diagnostic reagents during 2009~2020
III-6.4.3 Difference between demand and supply during 2009~2020
IV Cutting edge technology development in China
IV-1 Stem cell treatment
IV-2 Monoclonal antibody
IV-3 Diagnostic reagent
V Geographical distribution of China’s red biotechnology industry
V-1 Regional distribution
V-2 Introduction to RB industrial clusters
V-3 Overview of major RB industrial bases
V-3.1 Changsha Natioanl Biomedical Industrial Base
V-3.2 Zhangjiang National Biomedical Industrial Base
V-3.3 Zhongguancun National Biomedical Industrial Base
V-3.4 Shenzhen National Biological Industry Base
V-3.5 Changchun National Biological Industry Base
V-3.6 Guangzhou National Biological Industry Base
V-3.7 Shijiazhuang National Biological Industry Base
V-4 Forecast on national biological industry base in the next 5~10 years
VI Analysis of main Chinese companies in red biotechnology
VI-1 Choice of main Chinese companies in red biotechnology industry
VI-2 Analysis on main Chinese companies in red biotechnology industry
VI-2.1 Company engaged in biotech drugs
- Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.
VI-2.2 Companies engaged in blood products
- Shanghai RAAS Blood Products Co., Ltd.
- Hualan Biological Engineering,Inc.
VI-2.3 Company engaged in vaccine
- Beijing Tiantan Biological Products Co.,Ltd.
VI-2.4 Company engaged in bio-engineering drugs
- Beijing SL Pharmaceutical Co., Ltd.
VI-2.5 Company engaged in antibiotics
- Shangdong Lukang Pharmaceutical Co.,Ltd.
VI-2.6 Company engaged in diagnostic reagents
- Shanghai Kehua Bio-Engineering Co.,Ltd.
VII Main foreign involvement in China’s red biotechnology
VII-1 Foreign companies in China
VII-1.1 GlaxoSmithKline (China) Co., Ltd.
VII-1.2 Pfizer (China) Co., Ltd.
VII-1.3 Novartis (China) Co., Ltd.
VII-1.4 Sanofi Pasteur (China) Co., Ltd.
VII-2 Comparison of foreign companies and Chinese companies
VII-3 Forecast of foreign involvement in China in next 5~10 years
VII-3.1 Forecast on Novartis expansion in China
VII-3.2 Forecast on GSK expansion in China
VII-3.3 Forecast on Sanofi-aventis expansion in China
VIII Analysis of investment in the next 5 years
VIII-1 Investment opportunities in biopharmaceutical industry
VIII-1.1 Solid foundation of bio-pharmaceutical investment
VIII-1.2 Investment hotspots in China
VIII-2 Risk analysis of the investment in China’s red biotechnology
VIII-2.1 Risk from international environment
VIII-2.2 Risk from domestic environment
VIII-2.3 Estimation of bio-pharmaceutical investment risk in the next 5 years
IX Profiles of key players in China
IX-1.1 Gene recombinant drugs
IX-1.2 Blood products
IX-1.4 Diagnostic reagent
IX-2 Research institutes
LIST OF TABLES
Table II-1.1 Annual benchmark lending rate of RMB
Table II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009
Table II-3.1 Medicine industry output value in China, 2004-2008, billion USD
Table III-1.1.1 Market share of major EPO manufacturers, 2009
Table III-1.2.1 Three generations of insulin
Table III-1.2.2 Main rh-insulin manufacturers in China, 2009
Table III-1.3.1 Output of some G-CSF manufacturers, 2008
Table III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008
Table III-1.5.1 Top four interferon manufacturers in China, 2009
Table III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008
Table III-1.6.1 List of imported anti-tumor monoclonal antibody drugs
TableIII-1.6.2 List of domestic anti-tumor monoclonal antibody drugs
Table III-2.1 Some major human albumin manufacturers in China, 2010
Table III-2.2 Human albumin output of major manufacturers in China, 2008-2009
Table III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009
Table III-3.1 Vaccines belonging to National Immunization Program, 2010
Table III-3.2 Average import and export prices of human vaccines, 2006-2009
Table III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)
Table III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)
Table III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009
Table III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)
Table III-3.7 Major manufacturers’ HBV lot release situation, 2009 (unit: thousand doses)
Table III-3.8 Lot release volume of some major human vaccines, 2007-2009
Table III-4.1 Comparison of three main diagnostic reagents
Table III-4.3.1 Major diagnostic reagent producers in China, 2008
Table III-22.214.171.124 Top 3 producers of biochemical diagnostic reagents in China, 2008
Table III-126.96.36.199 Some producers of immunodiagnostic reagent in China, 2008
Table III-188.8.131.52.1 Major PCR reagent producers in China, 2008
Table III-184.108.40.206.1 Some biochips producers in China, 2009
Table III-220.127.116.11 Supply of four gene recombinant drugs in China, 2000-2020
Table III-18.104.22.168 Supply of gene recombinant drugs in China, 2009-2020
Table III-22.214.171.124 Demand for gene recombinant drugs in China, 2009-2020
Table III-126.96.36.199 Demand & supply gap of gene recombinant drugs in China, 2009-2020
Table III-188.8.131.52 Supply of blood products in China, 2005-2020
Table III-184.108.40.206 Demand for blood products in China, 2009-2020
Table III-220.127.116.11 Demand & supply gap of blood products in China, 2009-2020
- Shenyang Sunshine Pharmaceutical Co., Ltd.
- Hualan Biological Engineering Inc.
- Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
- Beijing Tiantan Biological Products Co., Ltd.
- Shanghai Kehua Bio-engineering Co., Ltd.